Decera Clinical Education Oncology Podcast – Details, episodes & analysis

Podcast details

Technical and general information from the podcast's RSS feed.

Decera Clinical Education Oncology Podcast

Decera Clinical Education

Education

Health & Fitness

Science

Frequency: 1 episode/8d. Total Eps: 266

Updates on new data and best practices in the care of patients with cancer across a wide variety of solid tumors and hematologic malignancies from Decera Clinical Education. Gain practical clinical insights and strategies and earn CME/CE credit for selected episodes.

Read moreCollapse

Site

RSS

Apple

Recent rankings

Latest chart positions across Apple Podcasts and Spotify rankings.

Apple Podcasts

🇩🇪 Germany - courses
27/08/2026
#78
🇩🇪 Germany - courses
26/08/2026
#71
🇩🇪 Germany - courses
25/08/2026
#55
🇩🇪 Germany - courses
24/08/2026
#35
🇩🇪 Germany - courses
19/08/2026
#98
🇩🇪 Germany - courses
18/08/2026
#80
🇩🇪 Germany - courses
17/08/2026
#58
🇩🇪 Germany - courses
16/08/2026
#40
🇺🇸 USA - courses
12/08/2026
#87
🇨🇦 Canada - courses
25/07/2026
#97

Spotify

No recent rankings available

Shared links between episodes and podcasts

Links found in episode descriptions and other podcasts that share them.

See all

RSS feed quality and score

Technical evaluation of the podcast's RSS feed quality and structure.

See all

RSS feed quality

To improve

Score global : 52%

Publication history

Monthly episode publishing history over the past years.

Year

Latest published episodes

Recent episodes with titles, durations, and descriptions.

See all

ROS1-Alterations and Molecular Testing in Advanced NSCLC

Episode 181

Wednesday, August 28, 2024 • Duration 16:28

In this episode, listen to Alice T. Shaw, MD, PhD, and Jessica J. Lin, MD, share their thoughts on the current understanding of ROS1 rearrangements in non-small-cell lung cancer tumor biology and its implications for molecular testing and treatment selection including:

ROS1-gene fusions in advanced lung cancer
ROS1 testing recommendations with DNA NGS, RNA NGS, FISH break apart assay, and IHC
Comparative specificity of ROS1 and ALK targeting tyrosine kinase inhibitors
Advantages of RNA- vs DNA-based next-generation sequencing

Program faculty:

Jessica J. Lin, MD
Attending Physician
Massachusetts General Hospital
Associate Professor of Medicine
Harvard Medical School
Boston, Massachusetts

Alice T. Shaw, MD, PhD
Chief, Strategic Partnerships
Attending Physician, Thoracic Oncology
Dana-Farber Cancer Institute
Harvard Medical School
Boston, Massachusetts

Resources:

To download the slides associated with this podcast discussion, please visit the program page

Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Read moreCollapse

Midyear Highlights of Key Data From 2024 Gynecologic Cancer Conferences Informing Treatment of Ovarian, Endometrial, and Cervical Cancers

Episode 180

Monday, August 5, 2024 • Duration 49:32

In this episode, listen to Floor J. Backes, MD, and Angeles Alvarez Secord, MD, MHSc, share their clinical insights and takeaways on new data presented for endometrial, ovarian, and cervical cancers presented at the 2024 annual meetings of the Society of Gynecologic Oncology and American Society of Clinical Oncology including:

RUBY Part 1 Subgroup Analyses by MRR Status: Addition of dostarlimab to platinum-based therapy followed by dostarlimab maintenance in advanced endometrial cancer
RUBY Part 2: Survival outcomes with addition of dostarlimab to platinum-based therapy followed by dostarlimab plus niraparib maintenance in advanced endometrial cancer
Survival Analyses From Phase III NRG GY018: Carboplatin plus paclitaxel with or without pembrolizumab as frontline treatment for patients with advanced endometrial cancer
DUO-E: First-line therapy with carboplatin plus paclitaxel plus bevacizumab and durvalumab followed by maintenance with bevacizumab, durvalumab, and olaparib in newly diagnosed endometrial cancer
Long-term Follow-up From SIENDO: PFS in TP53 wild-type and preliminary survival by molecular subgroups in patients with endometrial cancer and complete or partial response after ≥12 weeks of first line taxane/carboplatin
Subgroup Analyses From the Randomized Phase III MIRASOL: Mirvetuximab soravtansine vs investigator’s choice of chemotherapy in FR𝝰-high platinum-resistant ovarian cancer
Subgroup Analyses of Raludotatug Deruxtecan (R-DXd): An anti-CDH6 antibody–drug conjugate in previously treated ovarian cancer
Phase III CARACO Trial: Omission of lymphadenectomy in advanced ovarian cancer treated with interval cytoreductive surgery after neoadjuvant chemotherapy
innovaTV 301/ENGOT-cx12/GOG-3057: Tisotumab vedotin vs investigator’s choice of chemotherapy in patients with advanced cervical cancer
Randomized, Double-blind, Placebo-controlled Phase III Trial: Addition of pembrolizumab to concurrent chemoradiation in high-risk locally advanced cervical cancer

Program faculty:

Floor J. Backes, MD
Professor
Director of Clinical Research
Division of Gynecologic Oncology
Associate Fellowship Director
Department of Obstetrics and Gynecology
The Ohio State University College of Medicine
The James Cancer Hospital and Solove Research Institute
Columbus, Ohio

Angeles Alvarez Secord, MD, MHSc
Professor of Obstetrics & Gynecology
Division of Gynecologic OncologyDirector, Gynecologic Oncology Clinical TrialsAssociate Director, Clinical Research, Gynecologic Oncology ProgramDuke Cancer InstituteDuke University Medical CenterDurham, North Carolina

Applying the Latest Evidence and NCCN Guideline Recommendations in Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

Episode 169

Tuesday, May 7, 2024 • Duration 47:23

In this episode, Danielle M. Brander, MD; Deborah Stephens, DO; and Brian Hill, MD, PhD, discuss key aspects of the NCCN CLL guidelines and share strategies for applying these recommendations in your clinical practice to optimize treatment and outcomes. The greater discussion addresses:

Optimal selection of therapy for treatment-naive CLL, including second-generation covalent BTK inhibitors
Considerations in therapy selection for previously treated CLL
Novel strategies for treating CLL

Presenters:

Danielle M. Brander, MD
Assistant Professor of Medicine
Division of Hematologic Malignancies and Cellular Therapy
Duke Cancer Institute
Durham, North Carolina

Brian Hill, MD, PhD
Director, Lymphoid Malignancies Program
Staff Physician, Department of Hematology and Medical Oncology
Taussig Cancer Institute
Cleveland Clinic
Cleveland, Ohio

Deborah Stephens, DO
Associate Professor
Director of the CLL Program
Lineberger Comprehensive Cancer Center
University of North Carolina
Chapel Hill, North Carolina

Content based on a live and online CME program supported by educational grants from AstraZeneca; BeiGene, Ltd.; and Lilly.

Link to full program including downloadable slides:
https://bit.ly/49YxtSq

Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Managing Serious Adverse Events Associated with BTK Inhibitor Treatment

Episode 78

Tuesday, July 27, 2021 • Duration 13:13

In this podcast episode, Amy Goodrich, CRNP, discusses nursing perspectives on managing serious adverse events associated with BTK inhibitor therapy. Topics in this podcast include:

Atrial fibrillation
Cardiac toxicity
Musculoskeletal AEs
Managing risk of infections

Presenter:

Amy Goodrich, RN, MSN, CRNP-AC
Research Associate/Nurse Practitioner
Sidney Kimmel Comprehensive Cancer Center
Johns Hopkins University
Baltimore, Maryland

CE/AAPA credit available by visiting the online program:
https://bit.ly/3zMXFOp

Link to full program, including downloadable slidesets:
https://bit.ly/3iwN9Ub

Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Read moreCollapse

Strategies for Avoiding Adverse Reactions to BTK Inhibitor Therapy, Part 2: Patient Strategies for Self-Management

Episode 77

Tuesday, July 27, 2021 • Duration 17:50

In this podcast episode, Sandra E. Kurtin, PhD, ANP-C, AOCN, discusses nursing perspectives on avoiding adverse reactions to BTK inhibitor therapy. Topics in this second of 2 podcast episodes on avoiding AEs include:

Patient adherence to oral medications
Lifestyle changes
Monitoring, recording, and reporting of AEs
The role of the nurse
The role of the patient
AE management

Presenter:

Sandra E. Kurtin, PhD, ANP-C, AOCN
Director, Advanced Practice and Clinical Integration
The University of Arizona Cancer Center
Assistant Professor, Clinical Medicine
Adjunct Clinical Professor, Nursing
The University of Arizona
Tucson, Arizona

CE/AAPA credit available by visiting the online program:
https://bit.ly/3zMXFOp

Link to full program, including downloadable slidesets:
https://bit.ly/3iwN9Ub

Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Read moreCollapse

Strategies for Avoiding Adverse Reactions to BTK Inhibitor Therapy, Part 1: Drug–Drug and Drug–Food Interactions

Episode 76

Tuesday, July 27, 2021 • Duration 15:08

In this podcast episode,Sandra E. Kurtin, PhD, ANP-C, AOCN, discusses nursing perspectives on avoiding adverse reactions to BTK inhibitor therapy. Topics in this first of 2 podcasts on avoiding AEs include:

Pharmacokinetics
Drug metabolism
Drug–drug interactions
Drug–food interactions
The role of CYP enzymes
Foods to avoid
Medication review

Presenter:

CE/AAPA credit available by visiting the online program:
https://bit.ly/3zMXFOp

Link to full program, including downloadable slidesets:
https://bit.ly/3iwN9Ub

Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Read moreCollapse

BTK Inhibitors in CLL and Lymphomas: Overview and Current Indications

Episode 75

Friday, July 23, 2021 • Duration 13:46

In this podcast episode, Beth Faiman, PhD, MSN, APRN-BC, AOCN, provides a nursing-focused overview on available BTK inhibitors in the treatment of CLL and lymphomas. Topics in this podcast include:

Rationale for inhibiting BTK
MOA of BTK inhibitors
Approved BTK inhibitors
Recent clinical trial findings

Link to full program, including downloadable slidesets:
https://bit.ly/3iwN9Ub

Presenter:

Beth Faiman, PhD, MSN, APRN-BC, AOCN
Nurse Practitioner
Cleveland Clinic Taussig Cancer Institute
Cleveland, Ohio

Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Read moreCollapse

Adverse Events Associated with BTK Inhibitor Treatment

Episode 74

Friday, July 23, 2021 • Duration 12:30

In this podcast episode, Amy Goodrich, CRNP, discusses nursing perspectives on managing adverse events associated with BTK inhibitor therapy. Topics in this podcast include:

BTK inhibitor selectivity
BTK inhibitor adverse event profiles
Ibrutinib intolerance
Management of common adverse events

Presenter:

Amy Goodrich, RN, MSN, CRNP-AC
Research Associate/Nurse Practitioner
Sidney Kimmel Comprehensive Cancer Center
Johns Hopkins University
Baltimore, Maryland

CE/AAPA credit available by visiting the online program:
https://bit.ly/3zMXFOp

Link to full program, including downloadable slidesets:
https://bit.ly/3iwN9Ub

Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Read moreCollapse

Radiopharmaceuticals in the Treatment of Metastatic Castration-Resistant Prostate Cancer

Episode 72

Tuesday, July 20, 2021 • Duration 21:17

In this episode, Chris Parker, MD, and Bertrand Tombal, MD, PhD, discuss the clinical implications of the latest data on radiopharmaceuticals in the treatment of patients with metastatic castration-resistant prostate cancer (CRPC). Topics include:

Data from the PEACE-3 trial on the effect of bone-protective agents on fracture risk with enzalutamide plus radium-223
Efficacy and toxicity of PSMA lutetium plus standard of care in the VISION trial
Ongoing trials evaluating radionuclides in combination with other agents in metastatic CRPC

Presenters:

Chris Parker, MD
Professor of Prostate Oncology
Institute of Cancer Research
Clinical Oncologist
Department of Uro-oncology
Royal Marsden Hospital
Sutton, Surrey, United Kingdom

Bertrand Tombal, MD, PhD
Professor of Urology
Institut de Recherche Clinique (IRC)
Cliniques universitaires Saint-Luc
Chairman
Department of Surgery
Cliniques universitaires Saint-Luc
Brussels, Belgium

Link to full program, including downloadable slides:
https://bit.ly/36IEnNE

Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Read moreCollapse

How to Integrate Novel Treatment Classes for R/R Myeloma Into Clinical Practice: Information on BCMA-Targeted Therapies

Episode 71

Monday, July 19, 2021 • Duration 15:44

In this podcast episode, Donna Catamero, ANP-BC, OCN, CCRC, highlights practical considerations for integrating anti-BCMA–targeted therapy into clinical practice for patients with multiple myeloma after multiple relapses. Don’t forget to listen to part 1 of this series with a discussion on other novel treatment options by Tiffany Richards, PhD, ANP-BC, AOCNP, Nurse Practitioner at the University of Texas MD Anderson Cancer Center.

Presenter:

Donna Catamero, ANP-BC, OCN, CCRC
Associate Director, Myeloma Translational Research
The Mount Sinai Health System
New York, New York

CE/AAPA credit available by visiting the online program:
https://bit.ly/3zMXFOp

Link to full program, including downloadable slidesets:
https://bit.ly/3iwN9Ub

Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Read moreCollapse

Decera Clinical Education Oncology Podcast – Details, episodes & analysis

Podcast details

Recent rankings

Apple Podcasts

Spotify

Shared links between episodes and podcasts

RSS feed quality and score

Publication history

Latest published episodes

Related Shows Based on Content Similarities

Related Shows Based on Content Similarities

Apple Podcasts

Spotify

Decera Clinical Education Oncology Podcast – Details, episodes & analysis

Podcast details

Recent rankings

Apple Podcasts

Spotify

Shared links between episodes and podcasts

Other15

RSS feed quality and score

Publication history

Latest published episodes

Similar podcasts and content

Related Shows Based on Content Similarities

Other15

Related Shows Based on Content Similarities

Apple Podcasts

Spotify